Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page

Articles with the topic: clinical-trial

FDA approves a new drug for symptoms of Huntington's disease

FDA approves a new drug for symptoms of Huntington's disease

Dr Jeff Carroll on April 05, 2017

Significant news for the Huntington's disease community this week, as the USA's drug regulator, the FDA, has formally approved Austedo, also known as deutetrabenazine, for prescribing in HD. This modified form of tetrabenazine helps control chorea, the jerky movements often found in HD patients, but is taken twice rather than three times a day.

Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms

Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms

Dr Ed Wild on December 16, 2016

Pfizer has announced that the first-pass analysis of its 'Amaryllis' trial, testing a PDE-10 inhibitor drug, shows the drug did not meet its target of improving Huntington's disease symptoms. As a result, the open-label extension study will be stopped. This is not the news we'd been hoping for, but we've learned a lot about HD along the way.

Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease

Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease

Dr Jeff Carroll on September 30, 2016

A recent press release from Teva Pharmaceuticals has the HD community excited, claiming "Pridopidine Demonstrates Slowing of Progression of Huntington Disease in PRIDE-HD Study". What's pridopidine, and what can we really say about HD progression in patients treated with it?

Deutetrabenazine for Huntington's disease: a positive trial but the FDA says no? Not exactly...

Deutetrabenazine for Huntington's disease: a positive trial but the FDA says no? Not exactly...

Dr Peter McColgan on August 17, 2016

A scientific paper declares positive results for a trial of deutetrabenazine in Huntington's disease, but the headlines report the FDA has rejected the drug. Confusing stuff! The reality is positive overall for this new way of treating uncontrollable movements in HD, but patience will be needed to see where it all ends up.

Planting trees together: The 2016 Huntington's Disease Society of America Convention

Planting trees together: The 2016 Huntington's Disease Society of America Convention

Dr Jeff Carroll on June 13, 2016

Nearly a thousand HD family members converged on Baltimore, Maryland for the 2016 Huntington’s Disease Society of America’s Annual Convention. We normally don’t write reports from patient and family conferences, but there was something special about the atmosphere of this year’s Convention that compelled us to pen a brief update.

Thinking clearly about the earliest symptoms of HD and which brain regions control them

Thinking clearly about the earliest symptoms of HD and which brain regions control them

Dr Tamara Maiuri on April 18, 2016

Cognitive deficits, or difficulties thinking clearly, often appear well before the traditional clinical diagnosis of Huntington’s disease (HD). While many contend that the earliest cognitive deficits are caused by damage to the striatum – a structure deep in the brain known to be severely affected in HD – recent evidence suggests that this claim may paint an incomplete picture of the widespread changes occurring in the brains of HD patients during the very early stages of the disease.

How NOT to write a news article about a clinical trial

How NOT to write a news article about a clinical trial

Dr Jeff Carroll on March 11, 2016

A recent article in the UK newspaper the Daily Telegraph has HD families very excited. The title, "First drug to reverse Huntington’s disease begins human trials", certainly sounds exciting! But what's really going on? HDBuzz is here to help us untangle hope from hype in the huntingtin lowering world.

Huntington's Disease Therapeutics Conference 2016 - day 2

Huntington's Disease Therapeutics Conference 2016 - day 2

Dr Jeff Carroll on February 28, 2016

After an exciting day of science yesterday, day 2 saw updates on strategies to rid cells of the harmful mutant huntingtin protein and exciting reports on current and planned clinical trials.

Looking Past the Spin: Results from a Clinical Trial of Cysteamine

Looking Past the Spin: Results from a Clinical Trial of Cysteamine

Melissa Christianson on December 18, 2015

In early December, Raptor Pharmaceuticals released clinical trial results evaluating a drug called cysteamine in Huntington’s disease. News headlines about this trial are heavy on media spin, and so HDBuzz is here to break down what these new results really mean for the Huntington's community.